In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
42 authors.
Jasmin Coulombe-HuntingtonInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-0292-7654 Thierry BertomeuInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-5313-7057 Caroline HuardInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-9646-0500 Andrew Chatr-AryamontriInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-1589-9982 Daniel J St-CyrInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2432-6585 María Sánchez-OsunaProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-2505-3198 Karine NormandinInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.
Mohammadjavad PaydarInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0569-7017 Corinne St-DenisInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0009-0003-3629-9470 Li ZhangInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0009-0001-8476-3536 Henry SayProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0003-1788-1222 Roger PalouProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-7674-9358 Chris StarkProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0009-0000-4330-335X Bobby-Joe BreitkreutzProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0009-0002-7110-0044 Sandhya ManoharDepartment of Molecular Mechanisms of Disease, Universität Zürich, Zurich, Switzerland.ORCID 0000-0002-1322-3954 Hugo LavoieInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-0560-2409 Katherine L B BordenInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2188-5074 Damien D'AmoursOttawa Institute of Systems Biology, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0002-2183-9951 Alain VerreaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0466-9137 Sylvie MaderInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-6423-627X Sylvain MelocheInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-6201-7786 Marc TherrienInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-2047-7650 Pierre ThibaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-5993-0331 Brian WilhelmInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-9360-3887 Peter B DirksProgram in Developmental, Stem Cell & Cancer Biology, Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-5718-6465 John D AitchisonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Departments of Pediatrics and Biochemistry, University of Washington, WA, USA.ORCID 0000-0002-9153-6497 Elizabeth PattonMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-2570-0834 Philippe P RouxInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-5962-0250 Guy SauvageauInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-4333-7266 Trang HoangInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0001-7528-9142 Anne MarinierInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-0116-8345 Benjamin KwokDepartment of Oral Biology, College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, USA.ORCID 0000-0002-3668-7049 Vincent ArchambaultInstitute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0002-2857-7667 Mike TyersProgram in Molecular Medicine, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0002-9713-9994 Funding
BioGRID: An open resource for biological interactions and network analysisR01OD010929 · OD · SINAI HEALTH SYSTEM · PI KARA DOLINSKI, Mike Tyers · 2012 to 2026
$13.9MMechanistic Analysis of the Ubiquitin-Proteasome SystemR35GM127032 · NIGMS · HARVARD MEDICAL SCHOOL · PI RANDALL W KING · 2018 to 2026
$4.0MNIGMS NIH HHS R35 GM127032NIH HHS R01 OD010929
6 · The paper itselfAbstract
To probe drug mechanism of action (MOA) and interrogate the genetic architecture of human cells, we carried out isogenic genome-wide CRISPR/Cas9 knockout screens against 310 diverse drugs, bioactive compounds, and stress conditions. Stringent statistical correction for gene knockout fitness defects yielded a large-scale matrix of >12,000 high confidence chemical-genetic interactions (CGIs). This dataset revealed many previously unappreciated off-target effects for well-characterized compounds and novel MOAs for uncharacterized compounds. The CGI matrix uncovered dense genetic modules that yielded new biological insights into phospholipidosis, mitotic regulation, metabolism, the DNA damage response, and mTOR signaling. The dataset allowed identification of multi-drug sensitization and resistance mechanisms, inference of gene function, elaboration of cross-process connectivity, evaluation of the cell type specificity of CGIs, prediction of chemical synergism, and extensive annotation of understudied genes. This resource provides a map of the genetic landscape in human cells and a framework to help guide drug discovery.
Indexed as
chemical-genetic interactionchemical synergychemogenomic profileCRISPR/Cas9DNA damage responsedrug mechanismgene functionmitosismTORphospholipidosis
Identifiers
PMID41659671
PMCPMC12873861
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390